We are live on ! Find out more
PEAR

Pear Therapeutics, Inc. Class A Common Stock
PEAR

Delisted

PEAR was delisted on the 18th of April, 2023.

Back to rankings

72 hedge funds and large institutions have $203M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,400% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 1

654% more capital invested

Capital invested by funds: $26.9M → $203M (+$176M)

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

300% more funds holding

Funds holding: 18 → 72 (+54)

Holders
72
Holders Change
+54
Holders Change %
+300%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
55
Increased
7
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CM
Cohanzick Management
New York
+$13.8M
2
RA
RiverPark Advisors
New York
+$12.8M
3
AC
Aristeia Capital
Connecticut
+$11.8M
4
Nomura Holdings
Nomura Holdings
Japan
+$11.5M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.81M

Top Sellers

Rank Fund Capital Flow
1
OCM
Oribel Capital Management
New York
-$13.4K
2
BCM
Basso Capital Management
Connecticut
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
26
Mangrove Partners
Connecticut
$2.96M +$2.94M +299,693 New
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$2.74M +$2.72M +277,432 New
UOC
28
UBS O'Connor
Illinois
$2.47M – – –
CL
29
CSS LLC
Illinois
$2.13M +$2.11M +215,300 New
OCM
30
Oribel Capital Management
New York
$2.08M -$13.4K -1,368 -0.6%
BI
31
Bulldog Investors
New Jersey
$2.04M +$2.03M +206,730 New
PI
32
PEAK6 Investments
Illinois
$1.98M +$1.96M +199,898 New
AA
33
AQR Arbitrage
Connecticut
$1.87M +$1.86M +189,169 New
WP
34
Woodline Partners
California
$1.48M +$1.47M +150,104 New
PAMP
35
Polar Asset Management Partners
Ontario, Canada
$1.48M – – –
PMAM
36
Picton Mahoney Asset Management
Ontario, Canada
$1.48M +$1.47M +149,998 New
LP
37
LMR Partners
United Kingdom
$1.48M +$1.47M +150,000 New
HI
38
HBK Investments
Texas
$1.38M +$686K +69,957 +100%
Goldman Sachs
39
Goldman Sachs
New York
$1.29M +$892K +90,986 +230%
AWG
40
Alpha Wave Global
New York
$1.27M +$1.26M +128,166 New
Blackstone Inc
41
Blackstone Inc
New York
$1.24M +$1.23M +124,998 New
FTCM
42
Fir Tree Capital Management
New York
$989K – – –
AGC
43
Angelo Gordon & Co
New York
$988K +$981K +100,000 New
SCC
44
Spring Creek Capital
Kansas
$988K +$981K +100,000 New
SSA
45
Schonfeld Strategic Advisors
New York
$858K +$852K +86,890 New
LCS
46
Levin Capital Strategies
New York
$692K +$686K +69,999 New
Bank of America
47
Bank of America
North Carolina
$604K +$599K +61,132 New
WA
48
Whitebox Advisors
Minnesota
$497K – – –
CH
49
CVI Holdings
Delaware
$495K – – –
DCM
50
Dupont Capital Management
Delaware
$494K +$490K +49,998 New
1
2
3

PEAR Hedge Fund Activity: Q2 2021 in Review

72 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q2 2021, worth a combined $203M — up 654% from $26.9M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new PEAR positions and 1 closed out — a net gain of 54 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Cohanzick Management, opening a new position worth an estimated $13.8M. The largest seller was Oribel Capital Management, cutting an estimated $13.4K.

  • 72 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q2 2021, up from 18 in Q1 2021.
  • Funds reported $203M of Pear Therapeutics, Inc. Class A Common Stock stock for Q2 2021, up 654% quarter-over-quarter.
  • 55 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q2 2021 and 1 closed out, a net change of +54 holders.
  • The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q2 2021 was Cohanzick Management, an estimated $13.8M added.
  • The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q2 2021 was Oribel Capital Management, an estimated $13.4K sold.

Based on aggregated 13F filings for Q2 2021.